A Phase I trial of iLidcombe: Online treatment for young children who stutter

Ross, F; Onslow, M; Jones, M; Menzies, R; Packman, A; O'Brian, S; Hearne, A; Lowe, R

A Phase I trial of iLidcombe: Online treatment for young children who stutter

Ross, F Onslow, M

Jones, M Menzies, R

Packman, A

O'Brian, S

Hearne, A Lowe, R

Permalink

Publisher:: American Speech-Language-Hearing Association
Publication Type:: Journal Article
Citation:: American Journal of Speech-Language Pathology, 2026, pp. 1-12
Issue Date:: 2026-04-27

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted versionAdobe PDF (479.18 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Ross, F
dc.contributor.author	Onslow, M https://orcid.org/0000-0003-2629-2390
dc.contributor.author	Jones, M
dc.contributor.author	Menzies, R https://orcid.org/0000-0002-7589-960X
dc.contributor.author	Packman, A https://orcid.org/0000-0001-7378-326X
dc.contributor.author	O'Brian, S https://orcid.org/0000-0002-0882-1909
dc.contributor.author	Hearne, A
dc.contributor.author	Lowe, R https://orcid.org/0000-0003-3826-5306
dc.date.accessioned	2026-05-01T01:35:44Z
dc.date.available	2026-05-01T01:35:44Z
dc.date.issued	2026-04-27
dc.identifier.citation	American Journal of Speech-Language Pathology, 2026, pp. 1-12
dc.identifier.issn	1058-0360
dc.identifier.issn	1558-9110
dc.identifier.uri	http://hdl.handle.net/10453/194852
dc.description.abstract	AIM: The aim of this Phase I trial was to assess the safety, compliance, and potential efficacy of iLidcombe, a standalone internet version of the Lidcombe Program for young children who stutter. METHOD: We used a prospective single-group design involving 6 months of access to iLidcombe. Assessments occurred pretreatment and after 6 months of access. Participants were 20 parents of young children who stuttered. RESULTS: There was evidence of stuttering severity reduction after using iLidcombe for 6 months. Compliance with the program was favorable, and there was no suggestion of any psychologically adverse impact on children. CONCLUSION: The results of this Phase I trial provide a roadmap for further Phases II-IV clinical trial development.
dc.description.sponsorship	National Health and Medical Research Council [1132370]
dc.description.sponsorship	National Health and Medical Research Council [633007]
dc.language	eng
dc.publisher	American Speech-Language-Hearing Association
dc.relation	http://purl.org/au-research/grants/nhmrc/1132370
dc.relation	http://purl.org/au-research/grants/nhmrc/633007
dc.relation.ispartof	American Journal of Speech-Language Pathology
dc.relation.isbasedon	10.1044/2026_AJSLP-25-00448
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1103 Clinical Sciences, 1702 Cognitive Sciences, 2004 Linguistics
dc.subject.classification	Speech-Language Pathology & Audiology
dc.subject.classification	3903 Education systems
dc.subject.classification	4201 Allied health and rehabilitation science
dc.subject.classification	4704 Linguistics
dc.title	A Phase I trial of iLidcombe: Online treatment for young children who stutter
dc.type	Journal Article
utslib.location.activity	United States
utslib.for	1103 Clinical Sciences
utslib.for	1702 Cognitive Sciences
utslib.for	2004 Linguistics
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Australian Stuttering Research Centre (ASRC)
utslib.copyright.status	open_access	*
pubs.consider-herdc	true
dc.date.updated	2026-05-01T01:35:39Z
pubs.publication-status	Published online

Abstract:

AIM: The aim of this Phase I trial was to assess the safety, compliance, and potential efficacy of iLidcombe, a standalone internet version of the Lidcombe Program for young children who stutter. METHOD: We used a prospective single-group design involving 6 months of access to iLidcombe. Assessments occurred pretreatment and after 6 months of access. Participants were 20 parents of young children who stuttered. RESULTS: There was evidence of stuttering severity reduction after using iLidcombe for 6 months. Compliance with the program was favorable, and there was no suggestion of any psychologically adverse impact on children. CONCLUSION: The results of this Phase I trial provide a roadmap for further Phases II-IV clinical trial development.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/194852